Background: Recurrent vulvovaginal candidiasis (RVVC), is usually defined as three or more episodes of symptomatic vulvovaginal candidiasis (VVC) in Objective: To compare the effectiveness of intravaginal use of BA versus terconazole in the treatment of RVVC.
Patients and methods: This was a prospective randomized controlled study conducted on a total 70 females who were divided into two group; BA group (n=35) who received vaginal suppositories (600 mg/day) for two weeks and terconazole group (n=35) who received terconazole 80 mg vaginal suppository daily for six days. Mycological cure rate and improvement rates were evaluated on the 15^th day. Any reported adverse effects and recurrence rate were also assessed at third month follow-up.
Results: Vulval erythema was significantly increased among terconazole group compared to boric acid group. Treatment response was significantly improved among boric acid compared to terconazole one. No significant relation was recorded between response to treatment and complaints of the studied cases with mycological recurrence. Higher median parity was recorded among cases with mycological resistance than cases with mycological cure.
Conclusion: In the context of RVVC, boric acid seemed to be associated with promising outcomes as regards treatment outcomes with minimal adverse events compared to terconazole.